ArticleRSC advances2026
Pulmonary drug delivery of quercetin through scalable PEGylated mixed micelles of Gelucire® and Tetronic®.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many potent anticancer agents suffer from poor water solubility, limiting their industrial translation into effective formulations. Although single micellar systems have been explored to address this issue, they often exhibit low stability and encapsulation efficiency. To overcome these limitations, this study developed and characterized PEG-based mixed micelles composed of Gelucire® 48/16 and Tetronic® 1304 (T1304), aiming to improve the solubilization and cytotoxicity of a model lung cancer drug, quercetin (QCT). The micelles were extensively analysed using cloud point (CP), small-angle neutron scattering (SANS), and high-performance liquid chromatography (HPLC) techniques. SANS confirmed that Gelucire® 48/16 formed spherical or ellipsoidal micelles depending on composition with T1304. Micellar growth and improved drug encapsulation are noticed in saline conditions through the salting-out effect.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.